Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRAS | P01112 | 13/20 | 0.57 |
| ▸ | ESR1 | P03372 | 13/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 13/20 | 0.57 |
| ▸ | TOP1 | P11387 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5889605 | 0.86 | HRAS (0.73) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL30374497 | 0.78 | HRAS (0.62) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL30375233 | 0.77 | HRAS (0.71) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL30469493 | 0.76 | HRAS (0.79) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL7510361 | 0.74 | HRAS (0.76) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL30768134 | 0.73 | HRAS (0.69) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL30374803 | 0.73 | HRAS (0.69) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL10693609 | 0.73 | TOP1 (0.74) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL6976266 | 0.73 | HRAS (0.86) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL6963855 | 0.73 | HRAS (1.00) | HRASESR1ESR2TOP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064218-B2 | Aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. (US) | 2006-06-20 | — | — | US | disclosed |
| US-20030212113-A1 | Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity | GLAXOSMITHKLINE LLC | 2003-11-13 | — | — | US | disclosed |
| WO-2003057212-A1 | POLYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY | GENELABS TECHNOLOGIES, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212113-A1 | Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity | TYR, CYP51A1, ODC1 | HRAS 1040/4885ESR1 4541/4885ESR2 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.